Search

Your search keyword '"Greenberg, Peter"' showing total 1,386 results
Start Over Author "Greenberg, Peter"
1,386 results on '"Greenberg, Peter"'

2. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

Author

Aakash, Fnu, Gisriel, Savanah D., Zeidan, Amer M., Bennett, John M., Bejar, Rafael, Bewersdorf, Jan Philipp, Borate, Uma M., Boultwood, Jacqueline, Brunner, Andrew M., Buckstein, Rena, Carraway, Hetty E., Churpek, Jane E., Daver, Naval G., DeZern, Amy E., Efficace, Fabio, Fenaux, Pierre, Figueroa, Maria E., Garcia-Manero, Guillermo, Gore, Steven D., Greenberg, Peter L., Griffiths, Elizabeth A., Halene, Stephanie, Hourigan, Christopher S., Kim, Tae Kon, Kim, Nina, Komrokji, Rami S., Kutchroo, Vijay K., List, Alan F., Little, Richard F., Majeti, Ravindra, Nazha, Aziz, Nimer, Stephen D., Odenike, Olatoyosi, Padron, Eric, Patnaik, Mrinal M., Platzbecker, Uwe, Della Porta, Matteo G., Roboz, Gail J., Sallman, David A., Santini, Valeria, Sanz, Guillermo, Savona, Michael R., Sekeres, Mikkael A., Stahl, Maximilian, Starczynowski, Daniel T., Steensma, David P., Taylor, Justin, Abdel-Wahab, Omar, Wei, Andrew H., Xie, Zhuoer, Xu, Mina L., Hasserjian, Robert P., and Loghavi, Sanam

Published
2024
Full Text
View/download PDF

3. Molecular taxonomy of myelodysplastic syndromes and its clinical implications

Author

Bernard, Elsa, Hasserjian, Robert P., Greenberg, Peter L., Arango Ossa, Juan E., Creignou, Maria, Tuechler, Heinz, Gutierrez-Abril, Jesus, Domenico, Dylan, Medina-Martinez, Juan S., Levine, Max, Liosis, Konstantinos, Farnoud, Noushin, Sirenko, Maria, Jädersten, Martin, Germing, Ulrich, Sanz, Guillermo, van de Loosdrecht, Arjan A., Nannya, Yasuhito, Kosmider, Olivier, Follo, Matilde Y., Thol, Felicitas, Zamora, Lurdes, Pinheiro, Ronald F., Pellagatti, Andrea, Elias, Harold K., Haase, Detlef, Ganster, Christina, Ades, Lionel, Tobiasson, Magnus, Palomo, Laura, Della Porta, Matteo Giovanni, Fenaux, Pierre, Belickova, Monika, Savona, Michael R., Klimek, Virginia M., Santos, Fabio P. S., Boultwood, Jacqueline, Kotsianidis, Ioannis, Santini, Valeria, Solé, Francesc, Platzbecker, Uwe, Heuser, Michael, Valent, Peter, Finelli, Carlo, Voso, Maria Teresa, Shih, Lee-Yung, Fontenay, Michaela, Jansen, Joop H., Cervera, José, Gattermann, Norbert, Ebert, Benjamin L., Bejar, Rafael, Malcovati, Luca, Ogawa, Seishi, Cazzola, Mario, Hellström-Lindberg, Eva, and Papaemmanuil, Elli

Published
2024
Full Text
View/download PDF

4. Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.

Author

Steensma, David, Wermke, Martin, Klimek, Virginia, Greenberg, Peter, Font, Patricia, Komrokji, Rami, Yang, Jay, Brunner, Andrew, Carraway, Hetty, Ades, Lionel, Al-Kali, Aref, Alonso-Dominguez, Juan, Alfonso-Piérola, Ana, Coombs, Catherine, Deeg, H, Flinn, Ian, Foran, James, Garcia-Manero, Guillermo, Maris, Michael, McMasters, Malgorzata, Micol, Jean-Baptiste, De Oteyza, Jaime, Thol, Felicitas, Wang, Eunice, Watts, Justin, Taylor, Justin, Stone, Richard, Gourineni, Vikram, Marino, Alyssa, Yao, Huilan, Destenaves, Benoit, Yuan, Xiaobin, Yu, Kun, Dar, Sara, Ohanjanian, Lernik, Kuida, Keisuke, Xiao, Jianjun, Scholz, Catherine, Gualberto, Antonio, and Platzbecker, Uwe

Subjects
Administration, Oral, Aged, Aged, 80 and over, Biomarkers, Tumor, Dose-Response Relationship, Drug, Female, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Mutation, Missense, Myelodysplastic Syndromes, Patient Safety, Phosphoproteins, Piperazines, Pyridines, RNA Splicing Factors, Treatment Outcome
Abstract

We conducted a phase I clinical trial of H3B-8800, an oral small molecule that binds Splicing Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients (42 MDS, 4 CMML and 38 AML), 62 were red blood cell (RBC) transfusion dependent at study entry. Dose escalation cohorts examined two once-daily dosing regimens: schedule I (5 days on/9 days off, range of doses studied 1-40 mg, n = 65) and schedule II (21 days on/7 days off, 7-20 mg, n = 19); 27 patients received treatment for ≥180 days. The most common treatment-related, treatment-emergent adverse events included diarrhea, nausea, fatigue, and vomiting. No complete or partial responses meeting IWG criteria were observed; however, RBC transfusion free intervals >56 days were observed in nine patients who were transfusion dependent at study entry (15%). Of 15 MDS patients with missense SF3B1 mutations, five experienced RBC transfusion independence (TI). Elevated pre-treatment expression of aberrant transcripts of Transmembrane Protein 14C (TMEM14C), an SF3B1 splicing target encoding a mitochondrial porphyrin transporter, was observed in MDS patients experiencing RBC TI. In summary, H3B-8800 treatment was associated with mostly low-grade TAEs and induced RBC TI in a biomarker-defined subset of MDS.

Published
2021

6. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Author

Borate, Uma, Pugh, Kelly, Waller, Allyson, Welkie, Rina Li, Huang, Ying, Bewersdorf, Jan Philipp, Stahl, Maximilian, DeZern, Amy E., Platzbecker, Uwe, Sekeres, Mikkael A., Wei, Andrew H., Buckstein, Rena J., Roboz, Gail J., Savona, Michael R., Loghavi, Sanam, Hasserjian, Robert P., Fenaux, Pierre, Sallman, David A., Hourigan, Christopher S., Della Porta, Matteo Giovanni, Nimer, Stephen, Little, Richard F., Santini, Valeria, Efficace, Fabio, Taylor, Justin, Garcia-Manero, Guillermo, Odenike, Olatoyosi, Kim, Tae Kon, Halene, Stephanie, Komrokji, Rami S., Griffiths, Elizabeth A., Greenberg, Peter L., Xu, Mina L., Xie, Zhuoer, Bejar, Rafael, Sanz, Guillermo F., Patnaik, Mrinal M., Figueroa, Maria, Carraway, Hetty E., Abdel-Wahab, Omar, Starczynowski, Daniel, Padron, Eric, Boultwood, Jacqueline, Gore, Steven, Daver, Naval G., Churpek, Jane E., Majeti, Ravindra, Bennett, John M., List, Alan F., Brunner, Andrew M., and Zeidan, Amer M.

Published
2024
Full Text
View/download PDF

9. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

Author

Stahl, Maximilian, Bewersdorf, Jan Philipp, Xie, Zhuoer, Porta, Matteo Giovanni Della, Komrokji, Rami, Xu, Mina L., Abdel-Wahab, Omar, Taylor, Justin, Steensma, David P., Starczynowski, Daniel T., Sekeres, Mikkael A., Sanz, Guillermo, Sallman, David A., Roboz, Gail J., Platzbecker, Uwe, Patnaik, Mrinal M., Padron, Eric, Odenike, Olatoyosi, Nimer, Stephen D., Nazha, Aziz, Majeti, Ravi, Loghavi, Sanam, Little, Richard F., List, Alan F., Kim, Tae Kon, Hourigan, Christopher S., Hasserjian, Robert P., Halene, Stephanie, Griffiths, Elizabeth A., Gore, Steven D., Greenberg, Peter, Figueroa, Maria E., Fenaux, Pierre, Efficace, Fabio, DeZern, Amy E., Daver, Naval G., Churpek, Jane E., Carraway, Hetty E., Buckstein, Rena, Brunner, Andrew M., Boultwood, Jacqueline, Borate, Uma, Bejar, Rafael, Bennett, John M., Wei, Andrew H., Santini, Valeria, Savona, Michael R., and Zeidan, Amer M.

Published
2023
Full Text
View/download PDF

10. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Author

Bernard, Elsa, Nannya, Yasuhito, Hasserjian, Robert P, Devlin, Sean M, Tuechler, Heinz, Medina-Martinez, Juan S, Yoshizato, Tetsuichi, Shiozawa, Yusuke, Saiki, Ryunosuke, Malcovati, Luca, Levine, Max F, Arango, Juan E, Zhou, Yangyu, Solé, Francesc, Cargo, Catherine A, Haase, Detlef, Creignou, Maria, Germing, Ulrich, Zhang, Yanming, Gundem, Gunes, Sarian, Araxe, van de Loosdrecht, Arjan A, Jädersten, Martin, Tobiasson, Magnus, Kosmider, Olivier, Follo, Matilde Y, Thol, Felicitas, Pinheiro, Ronald F, Santini, Valeria, Kotsianidis, Ioannis, Boultwood, Jacqueline, Santos, Fabio PS, Schanz, Julie, Kasahara, Senji, Ishikawa, Takayuki, Tsurumi, Hisashi, Takaori-Kondo, Akifumi, Kiguchi, Toru, Polprasert, Chantana, Bennett, John M, Klimek, Virginia M, Savona, Michael R, Belickova, Monika, Ganster, Christina, Palomo, Laura, Sanz, Guillermo, Ades, Lionel, Della Porta, Matteo Giovanni, Elias, Harold K, Smith, Alexandra G, Werner, Yesenia, Patel, Minal, Viale, Agnès, Vanness, Katelynd, Neuberg, Donna S, Stevenson, Kristen E, Menghrajani, Kamal, Bolton, Kelly L, Fenaux, Pierre, Pellagatti, Andrea, Platzbecker, Uwe, Heuser, Michael, Valent, Peter, Chiba, Shigeru, Miyazaki, Yasushi, Finelli, Carlo, Voso, Maria Teresa, Shih, Lee-Yung, Fontenay, Michaela, Jansen, Joop H, Cervera, José, Atsuta, Yoshiko, Gattermann, Norbert, Ebert, Benjamin L, Bejar, Rafael, Greenberg, Peter L, Cazzola, Mario, Hellström-Lindberg, Eva, Ogawa, Seishi, and Papaemmanuil, Elli

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Hematology, Stem Cell Research, Cancer, Clinical Research, Rare Diseases, Genetics, 2.1 Biological and endogenous factors, Aetiology, Alleles, Cohort Studies, DNA Copy Number Variations, DNA Mutational Analysis, Female, Gene Frequency, Genomic Instability, Humans, Loss of Heterozygosity, Male, Mutation, Myelodysplastic Syndromes, Phenotype, Prognosis, Survival Analysis, Treatment Outcome, Tumor Suppressor Protein p53, Medical and Health Sciences, Immunology, Biomedical and clinical sciences, Health sciences
Abstract

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease3,4, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies6-8 and dismal outcomes9. Consistent with the tumor-suppressive role of TP53, patients harbor both mono- and biallelic mutations10. However, the biological and clinical implications of TP53 allelic state have not been fully investigated in MDS or any other cancer type. We analyzed 3,324 patients with MDS for TP53 mutations and allelic imbalances and delineated two subsets of patients with distinct phenotypes and outcomes. One-third of TP53-mutated patients had monoallelic mutations whereas two-thirds had multiple hits (multi-hit) consistent with biallelic targeting. Established associations with complex karyotype, few co-occurring mutations, high-risk presentation and poor outcomes were specific to multi-hit patients only. TP53 multi-hit state predicted risk of death and leukemic transformation independently of the Revised International Prognostic Scoring System (IPSS-R)11. Surprisingly, monoallelic patients did not differ from TP53 wild-type patients in outcomes and response to therapy. This study shows that consideration of TP53 allelic state is critical for diagnostic and prognostic precision in MDS as well as in future correlative studies of treatment response.

Published
2020

11. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

Author

Zeidan, Amer M., Bewersdorf, Jan Philipp, Buckstein, Rena, Sekeres, Mikkael A., Steensma, David P., Platzbecker, Uwe, Loghavi, Sanam, Boultwood, Jacqueline, Bejar, Rafael, Bennett, John M., Borate, Uma, Brunner, Andrew M., Carraway, Hetty, Churpek, Jane E., Daver, Naval G., Della Porta, Matteo, DeZern, Amy E., Efficace, Fabio, Fenaux, Pierre, Figueroa, Maria E., Greenberg, Peter, Griffiths, Elizabeth A., Halene, Stephanie, Hasserjian, Robert P., Hourigan, Christopher S., Kim, Nina, Kim, Tae Kon, Komrokji, Rami S., Kutchroo, Vijay, List, Alan F., Little, Richard F., Majeti, Ravi, Nazha, Aziz, Nimer, Stephen D., Odenike, Olatoyosi, Padron, Eric, Patnaik, Mrinal M., Roboz, Gail J., Sallman, David A., Sanz, Guillermo, Stahl, Maximilian, Starczynowski, Daniel T., Taylor, Justin, Xie, Zhuoer, Xu, Mina, Savona, Michael R., Wei, Andrew H., Abdel-Wahab, Omar, and Santini, Valeria

Published
2022
Full Text
View/download PDF

12. MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways

Author

Youn, Minyoung, Huang, Haigen, Chen, Cheng, Kam, Sharon, Wilkes, Mark C, Chae, Hee-Don, Sridhar, Kunju J, Greenberg, Peter L, Glader, Bertil, Narla, Anupama, Lin, Shuo, and Sakamoto, Kathleen M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Stem Cell Research - Embryonic - Non-Human, Hematology, Cancer, Stem Cell Research, Rare Diseases, Blood, Erythropoiesis, Humans, Matrix Metalloproteinase 9, Transforming Growth Factor beta, Cardiovascular medicine and haematology
Abstract

The del(5q) myelodysplastic syndrome (MDS) is a distinct subtype of MDS, associated with deletion of the ribosomal protein S14 (RPS14) gene that results in macrocytic anemia. This study sought to identify novel targets for the treatment of patients with del(5q) MDS by performing an in vivo drug screen using an rps14-deficient zebrafish model. From this, we identified the secreted gelatinase matrix metalloproteinase 9 (MMP9). MMP9 inhibitors significantly improved the erythroid defect in rps14-deficient zebrafish. Similarly, treatment with MMP9 inhibitors increased the number of colony forming unit-erythroid colonies and the CD71+ erythroid population from RPS14 knockdown human BMCD34+ cells. Importantly, we found that MMP9 expression is upregulated in RPS14-deficient cells by monocyte chemoattractant protein 1. Double knockdown of MMP9 and RPS14 increased the CD71+ population compared with RPS14 single knockdown, suggesting that increased expression of MMP9 contributes to the erythroid defect observed in RPS14-deficient cells. In addition, transforming growth factor β (TGF-β) signaling is activated in RPS14 knockdown cells, and treatment with SB431542, a TGF-β inhibitor, improved the defective erythroid development of RPS14-deficient models. We found that recombinant MMP9 treatment decreases the CD71+ population through increased SMAD2/3 phosphorylation, suggesting that MMP9 directly activates TGF-β signaling in RPS14-deficient cells. Finally, we confirmed that MMP9 inhibitors reduce SMAD2/3 phosphorylation in RPS14-deficient cells to rescue the erythroid defect. In summary, these study results support a novel role for MMP9 in the pathogenesis of del(5q) MDS and the potential for the clinical use of MMP9 inhibitors in the treatment of patients with del(5q) MDS.

Published
2019

13. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Author

Haase, Detlef, Stevenson, Kristen E, Neuberg, Donna, Maciejewski, Jaroslaw P, Nazha, Aziz, Sekeres, Mikkael A, Ebert, Benjamin L, Garcia-Manero, Guillermo, Haferlach, Claudia, Haferlach, Torsten, Kern, Wolfgang, Ogawa, Seishi, Nagata, Yasunobu, Yoshida, Kenichi, Graubert, Timothy A, Walter, Matthew J, List, Alan F, Komrokji, Rami S, Padron, Eric, Sallman, David, Papaemmanuil, Elli, Campbell, Peter J, Savona, Michael R, Seegmiller, Adam, Adès, Lionel, Fenaux, Pierre, Shih, Lee-Yung, Bowen, David, Groves, Michael J, Tauro, Sudhir, Fontenay, Michaela, Kosmider, Olivier, Bar-Natan, Michal, Steensma, David, Stone, Richard, Heuser, Michael, Thol, Felicitas, Cazzola, Mario, Malcovati, Luca, Karsan, Aly, Ganster, Christina, Hellström-Lindberg, Eva, Boultwood, Jacqueline, Pellagatti, Andrea, Santini, Valeria, Quek, Lynn, Vyas, Paresh, Tüchler, Heinz, Greenberg, Peter L, Bejar, Rafael, and International Working Group for MDS Molecular Prognostic Committee

Subjects
International Working Group for MDS Molecular Prognostic Committee, Humans, Myelodysplastic Syndromes, Chromosome Aberrations, Prognosis, Combined Modality Therapy, Survival Rate, Follow-Up Studies, Karyotyping, Mutation, Aged, Aged, 80 and over, Middle Aged, Female, Male, Tumor Suppressor Protein p53, Biomarkers, Tumor, Hematology, Rare Diseases, Genetics, Clinical Sciences, Oncology and Carcinogenesis, Immunology
Abstract

Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS). Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic abnormalities, which is a highly adverse prognostic marker. However, CK-MDS can carry a wide range of chromosomal abnormalities and somatic mutations. To refine risk stratification of CK-MDS patients, we examined data from 359 CK-MDS patients shared by the International Working Group for MDS. Mutations were underrepresented with the exception of TP53 mutations, identified in 55% of patients. TP53 mutated patients had even fewer co-mutated genes but were enriched for the del(5q) chromosomal abnormality (p 10%), abnormal 3q, abnormal 9, and monosomy 7 as having the greatest survival risk. The poor risk associated with CK-MDS is driven by its association with prognostically adverse TP53 mutations and can be refined by considering clinical and karyotype features.

Published
2019

15. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

Author

Komrokji, Rami S., Platzbecker, Uwe, Fenaux, Pierre, Zeidan, Amer M., Garcia-Manero, Guillermo, Mufti, Ghulam J., Santini, Valeria, Díez-Campelo, María, Finelli, Carlo, Jurcic, Joseph G., Greenberg, Peter L., Sekeres, Mikkael A., DeZern, Amy E., Savona, Michael R., Shetty, Jeevan K., Ito, Rodrigo, Zhang, George, Ha, Xianwei, Backstrom, Jay T., and Verma, Amit

Published
2022
Full Text
View/download PDF

17. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

Author

Efficace, Fabio, primary, Buckstein, Rena, additional, Abel, Gregory A., additional, Giesinger, Johannes M., additional, Fenaux, Pierre, additional, Bewersdorf, Jan Philipp, additional, Brunner, Andrew M., additional, Bejar, Rafael, additional, Borate, Uma, additional, DeZern, Amy E., additional, Greenberg, Peter, additional, Roboz, Gail J., additional, Savona, Michael R., additional, Sparano, Francesco, additional, Boultwood, Jacqueline, additional, Komrokji, Rami, additional, Sallman, David A., additional, Xie, Zhuoer, additional, Sanz, Guillermo, additional, Carraway, Hetty E., additional, Taylor, Justin, additional, Nimer, Stephen D., additional, Della Porta, Matteo Giovanni, additional, Santini, Valeria, additional, Stahl, Maximilian, additional, Platzbecker, Uwe, additional, Sekeres, Mikkael A., additional, and Zeidan, Amer M., additional

Published
2024
Full Text
View/download PDF

18. Burket's Oral Medicine

Author

Michael Glick, Martin S. Greenberg, Peter B. Lockhart, Stephen J. Challacombe, Michael Glick, Martin S. Greenberg, Peter B. Lockhart, Stephen J. Challacombe

Published
2021

19. p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.

Author

Brar, Nivaz, Lawrence, Lauren, Fung, Eula, Zehnder, James L, Greenberg, Peter L, Mannis, Gabriel N, Zhang, Tian Y, Gratzinger, Dita, Oak, Jean, Silva, Oscar, Kurzer, Jason, Tan, Brent, Menke, Joshua R, and Fernandez-Pol, Sebastian

Subjects
ACUTE myeloid leukemia, BONE marrow cells, MYELODYSPLASTIC syndromes, MYELOID cells, BONE marrow
Abstract

Objectives Measurable residual disease flow cytometry (MRD-FC) and molecular studies are the most sensitive methods for detecting residual malignant populations after therapy for TP53 -mutated acute myeloid leukemia and myelodysplastic neoplasms (TP53+ AML/MDS). However, their sensitivity is limited in suboptimal aspirates or when the immunophenotype of the neoplastic blasts overlaps with erythroids or normal maturing myeloid cells. In this study, we set out to determine if p53 immunohistochemistry (IHC) correlates with MRD-FC and next-generation sequencing (NGS) in the posttherapy setting and to determine the utility of p53 IHC to detect residual disease in the setting of negative or equivocal MRD-FC. Methods We retrospectively identified 28 pre- and posttherapy bone marrow biopsy specimens from 9 patients with TP53+ AML/MDS and a p53 overexpressor phenotype by IHC (strong 3+ staining at initial diagnosis). Next-generation sequencing and/or MRD-FC results were collected for each specimen. Results Using a threshold of more than ten 2-3+ cells in any one 400× field, p53 IHC detected residual disease with a sensitivity of 94% and a specificity of 89%. The threshold used in this study showed a high degree of concordance among 6 blinded pathologists (Fleiss κ = 0.97). Conclusions Our study suggests that p53 IHC can be used as a rapid tool (within 24 hours) to aid in the detection of residual disease that may complement MRD-FC or NGS in cases in which the flow cytometry immunophenotype is equivocal and/or the bone marrow aspirate is suboptimal. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations

Author

Feurstein, Simone, Adegunsoye, Ayodeji, Mojsilovic, Danijela, Vij, Rekha, West DePersia, Allison H., Rajagopal, Padma Sheila, Osman, Afaf, Collins, Robert H., Kim, Raymond H., Gore, Steven D., Greenberg, Peter, Godley, Lucy A., Li, Zejuan, del Gaudio, Daniela, Subramanian, Hari Prasanna, Das, Soma, Walsh, Tom, Gulsuner, Suleyman, Segal, Jeremy P., Husain, Aliya N., Gurbuxani, Sandeep, King, Mary-Claire, Strek, Mary E., and Churpek, Jane E.

Published
2020
Full Text
View/download PDF

21. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Author

Malcovati, Luca, Stevenson, Kristen, Papaemmanuil, Elli, Neuberg, Donna, Bejar, Rafael, Boultwood, Jacqueline, Bowen, David T., Campbell, Peter J., Ebert, Benjamin L., Fenaux, Pierre, Haferlach, Torsten, Heuser, Michael, Jansen, Joop H., Komrokji, Rami S., Maciejewski, Jaroslaw P., Walter, Matthew J., Fontenay, Michaela, Garcia-Manero, Guillermo, Graubert, Timothy A., Karsan, Aly, Meggendorfer, Manja, Pellagatti, Andrea, Sallman, David A., Savona, Michael R., Sekeres, Mikkael A., Steensma, David P., Tauro, Sudhir, Thol, Felicitas, Vyas, Paresh, Van de Loosdrecht, Arjan A., Haase, Detlef, Tüchler, Heinz, Greenberg, Peter L., Ogawa, Seishi, Hellstrom-Lindberg, Eva, and Cazzola, Mario

Published
2020
Full Text
View/download PDF

23. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

Author

Sirenko, Maria, primary, Bernard, Elsa, additional, Creignou, Maria, additional, Domenico, Dylan, additional, Farina, Andrea, additional, Arango Ossa, Juan Esteban, additional, Kosmider, Olivier, additional, Hasserjian, Robert P, additional, Jädersten, Martin, additional, Germing, Ulrich, additional, Sanz, Guillermo F., additional, van de Loosdrecht, Arjan A., additional, Gurnari, Carmelo, additional, Follo, Matilde Y, additional, Thol, Felicitas R., additional, Zamora, Lurdes, additional, Pellagatti, Andrea, additional, Elias, Harold Kunal, additional, Haase, Detlef Thomas, additional, Sander, Birgitta, additional, Orna, Elisa, additional, Zoldan, Katharina, additional, Eder, Lea Naomi, additional, Sperr, Wolfgang R, additional, Thalhammer, Renate, additional, Ganster, Christina, additional, Adès, Lionel, additional, Tobiasson, Magnus, additional, Palomo, Laura, additional, Della Porta, Matteo Giovanni, additional, Huberman, Kety H, additional, Fenaux, Pierre, additional, Belickova, Monika, additional, Savona, Michael R., additional, Klimek, Virginia, additional, Santos, Fabio P S, additional, Boultwood, Jacqueline, additional, Kotsianidis, Ioannis, additional, Santini, Valeria, additional, Sole, Francesc, additional, Platzbecker, Uwe, additional, Heuser, Michael, additional, Valent, Peter, additional, Finelli, Carlo, additional, Voso, Maria Teresa, additional, Shih, Lee Yung, additional, Ogawa, Seishi, additional, Fontenay, Michaela, additional, Jansen, Joop H, additional, Cervera, José, additional, Ebert, Benjamin L, additional, Bejar, Rafael, additional, Greenberg, Peter L., additional, Gattermann, Norbert, additional, Malcovati, Luca, additional, Cazzola, Mario, additional, Beck, David B., additional, Hellstrom-Lindberg, Eva S, additional, Papaemmanuil, Elli, additional, and Pinheiro, Ronald Feitosa, additional

Published
2024
Full Text
View/download PDF

24. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Author

Tefferi, Ayalew, Kantarjian, Hagop, Rajkumar, S Vincent, Baker, Lawrence H, Abkowitz, Jan L, Adamson, John W, Advani, Ranjana Hira, Allison, James, Antman, Karen H, Bast, Robert C, Bennett, John M, Benz, Edward J, Berliner, Nancy, Bertino, Joseph, Bhatia, Ravi, Bhatia, Smita, Bhojwani, Deepa, Blanke, Charles D, Bloomfield, Clara D, Bosserman, Linda, Broxmeyer, Hal E, Byrd, John C, Cabanillas, Fernando, Canellos, George Peter, Chabner, Bruce A, Chanan-Khan, Asher, Cheson, Bruce, Clarkson, Bayard, Cohn, Susan L, Colon-Otero, Gerardo, Cortes, Jorge, Coutre, Steven, Cristofanilli, Massimo, Curran, Walter J, Daley, George Q, DeAngelo, Daniel J, Deeg, H Joachim, Einhorn, Lawrence H, Erba, Harry P, Esteva, Francisco J, Estey, Elihu, Fidler, Isaiah J, Foran, James, Forman, Stephen, Freireich, Emil, Fuchs, Charles, George, James N, Gertz, Morie A, Giralt, Sergio, Golomb, Harvey, Greenberg, Peter, Gutterman, Jordan, Handin, Robert I, Hellman, Samuel, Hoff, Paulo Marcelo, Hoffman, Ronald, Hong, Waun Ki, Horowitz, Mary, Hortobagyi, Gabriel N, Hudis, Clifford, Issa, Jean Pierre, Johnson, Bruce Evan, Kantoff, Philip W, Kaushansky, Kenneth, Khayat, David, Khuri, Fadlo R, Kipps, Thomas J, Kripke, Margaret, Kyle, Robert A, Larson, Richard A, Lawrence, Theodore S, Levine, Ross, Link, Michael P, Lippman, Scott M, Lonial, Sagar, Lyman, Gary H, Markman, Maurie, Mendelsohn, John, Meropol, Neal J, Messinger, Yoav, Mulvey, Therese M, O'Brien, Susan, Perez-Soler, Roman, Pollock, Raphael, Prchal, Josef, Press, Oliver, Radich, Jerald, Rai, Kanti, Rosenberg, Saul A, Rowe, Jacob M, Rugo, Hope, Runowicz, Carolyn D, Sandmaier, Brenda M, Saven, Alan, Schafer, Andrew I, Schiffer, Charles, Sekeres, Mikkael A, Silver, Richard T, Siu, Lillian L, and Steensma, David P

Subjects
Humans, Neoplasms, Antineoplastic Agents, Patient Advocacy, Patient Participation, Drug Costs, Prescription Fees, United States, Medical and Health Sciences
Published
2015

25. MDS prognostic scoring systems – Past, present, and future

Author

Jonas, Brian A and Greenberg, Peter L

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Rare Diseases, Hematology, Genetics, Cancer, Antineoplastic Agents, Bone Marrow Cells, Cell Proliferation, Disease Progression, Gene Expression, Humans, Immunophenotyping, Karyotyping, Leukemia, Myeloid, Acute, Mutation, Myelodysplastic Syndromes, Neoplasm Proteins, Prognosis, Research Design, Survival Analysis, myelodysplastic syndromes, prognosis, cytogenetics, flow cytometry, mutations, gene expression, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid haemopathies characterized by defective differentiation of haematopoietic cells and expansion of the abnormal clone. This leads to bone marrow failure with the resulting peripheral blood cytopenias and evolution to or toward acute myeloid leukaemia that characterize MDS clinically. The clinical heterogeneity of MDS has led several groups to analyze patient and clinical characteristics to develop prognostic scoring systems yielding estimates of overall and leukaemia-free survival to guide clinical decision-making. These models have evolved over time as our understanding of the pathogenesis, natural history, and treatment of MDS has improved. Rapid advances in flow cytometric analysis, adjuncts to standard metaphase cytogenetics, and gene mutation analysis are revolutionizing our understanding of MDS pathogenesis and prognosis. Despite the existence of multiple well-validated prognostic scoring systems, further refinements of current models with these new sources of prognostic data are needed and are described herein.

Published
2015

27. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS

Author

Miyazaki, Yasushi, Tuechler, Heinz, Sanz, Guillermo, Schanz, Julie, Garcia-Manero, Guillermo, Solé, Francesc, Bennett, John M., Bowen, David, Fenaux, Pierre, Dreyfus, Francois, Kantarjian, Hagop, Kuendgen, Andrea, Malcovati, Luca, Cazzola, Mario, Cermak, Jaroslav, Fonatsch, Christa, Le Beau, Michelle M., Slovak, Marilyn L., Santini, Valeria, Lübbert, Michael, Maciejewski, Jaroslaw, Machherndl-Spandl, Sigrid, Magalhaes, Silvia M.M., Pfeilstöcker, Michael, Sekeres, Mikkael A., Sperr, Wolfgang R., Stauder, Reinhard, Tauro, Sudhir, Valent, Peter, Vallespi, Teresa, van de Loosdrecht, Arjan A., Germing, Ulrich, Haase, Detlef, and Greenberg, Peter L.

Published
2018
Full Text
View/download PDF

28. Shared and Distinct Mechanisms of UBA1 Inactivation Across Different Diseases

Author

Collins, Jason C, primary, Magaziner, Samuel J, additional, English, Maya, additional, Hassan, Bakar, additional, Chen, Xiang, additional, Balanda, Nicholas, additional, Anderson, Meghan, additional, Lam, Athena, additional, Fernandez-Pol, Sebastian, additional, Kwong, Bernice, additional, Greenberg, Peter L, additional, Terrier, Benjamin, additional, Likhite, Mary E, additional, Kosmider, Olivier, additional, Wang, Yan, additional, Samara, Nadine L, additional, Walters, Kylie J, additional, Beck, David B, additional, and Werner, Achim, additional

Published
2023
Full Text
View/download PDF

29. Updates in classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium of MDS (icMDS)

Author

Stahl, Maximilian, primary, Bewersdorf, Jan Philipp, additional, Xie, Zhuoer, additional, Porta, Matteo Giovanni Della, additional, Komrokji, Rami, additional, Xu, Mina L., additional, Abdel-Wahab, Omar, additional, Taylor, Justin, additional, Steensma, David P., additional, Starczynowski, Daniel T., additional, Sekeres, Mikkael A., additional, Sanz, Guillermo, additional, Sallman, David A., additional, Roboz, Gail J., additional, Platzbecker, Uwe, additional, Patnaik, Mrinal M., additional, Padron, Eric, additional, Odenike, Olatoyosi, additional, Nimer, Stephen D., additional, Nazha, Aziz, additional, Majeti, Ravi, additional, Loghavi, Sanam, additional, Little, Richard F., additional, List, Alan F., additional, Kim, Tae Kon, additional, Hourigan, Christopher S., additional, Hasserjian, Robert P., additional, Halene, Stephanie, additional, Griffiths, Elizabeth A., additional, Gore, Steven D., additional, Greenberg, Peter, additional, Figueroa, Maria E., additional, Fenaux, Pierre, additional, Efficace, Fabio, additional, DeZern, Amy E., additional, Daver, Naval G., additional, Churpek, Jane E., additional, Carraway, Hetty E., additional, Buckstein, Rena, additional, Brunner, Andrew M., additional, Boultwood, Jacqueline, additional, Borate, Uma, additional, Bejar, Rafael, additional, Bennett, John M., additional, Wei, Andrew H., additional, Santini, Valeria, additional, Savona, Michael R., additional, and Zeidan, Amer M., additional

Published
2023
Full Text
View/download PDF

30. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study

Author

Swords, Ronan T., Greenberg, Peter L., Wei, Andrew H., Durrant, Simon, Advani, Anjali S., Hertzberg, Mark S., Lewis, Ian D., Rivera, Gabriel, Gratzinger, Dita, Fan, Alice C., Felsher, Dean W., Cortes, Jorge E., Watts, Justin M., Yarranton, Geoff T., Walling, Jackie M., and Lancet, Jeffrey E.

Published
2016
Full Text
View/download PDF

31. Time-dependent changes in mortality and transformation risk in MDS

Author

Pfeilstöcker, Michael, Tuechler, Heinz, Sanz, Guillermo, Schanz, Julie, Garcia-Manero, Guillermo, Solé, Francesc, Bennett, John M., Bowen, David, Fenaux, Pierre, Dreyfus, Francois, Kantarjian, Hagop, Kuendgen, Andrea, Malcovati, Luca, Cazzola, Mario, Cermak, Jaroslav, Fonatsch, Christa, Le Beau, Michelle M., Slovak, Marilyn L., Levis, Alessandro, Luebbert, Michael, Maciejewski, Jaroslaw, Machherndl-Spandl, Sigrid, Magalhaes, Silvia M.M., Miyazaki, Yasushi, Sekeres, Mikkael A., Sperr, Wolfgang R., Stauder, Reinhard, Tauro, Sudhir, Valent, Peter, Vallespi, Teresa, van de Loosdrecht, Arjan A., Germing, Ulrich, Haase, Detlef, and Greenberg, Peter L.

Published
2016
Full Text
View/download PDF

32. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

Author

Garcia-Manero, Guillermo, Fenaux, Pierre, Al-Kali, Aref, Baer, Maria R, Sekeres, Mikkael A, Roboz, Gail J, Gaidano, Gianluca, Scott, Bart L, Greenberg, Peter, Platzbecker, Uwe, Steensma, David P, Kambhampati, Suman, Kreuzer, Karl-Anton, Godley, Lucy A, Atallah, Ehab, Collins, Robert, Jr, Kantarjian, Hagop, Jabbour, Elias, Wilhelm, Francois E, Azarnia, Nozar, and Silverman, Lewis R

Published
2016
Full Text
View/download PDF

33. Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Author

Bernard, Elsa, Nannya, Yasuhito, Hasserjian, Robert P., Devlin, Sean M., Tuechler, Heinz, Medina-Martinez, Juan S., Yoshizato, Tetsuichi, Shiozawa, Yusuke, Saiki, Ryunosuke, Malcovati, Luca, Levine, Max F., Arango, Juan E., Zhou, Yangyu, Solé, Francesc, Cargo, Catherine A., Haase, Detlef, Creignou, Maria, Germing, Ulrich, Zhang, Yanming, Gundem, Gunes, Sarian, Araxe, van de Loosdrecht, Arjan A., Jädersten, Martin, Tobiasson, Magnus, Kosmider, Olivier, Follo, Matilde Y., Thol, Felicitas, Pinheiro, Ronald F., Santini, Valeria, Kotsianidis, Ioannis, Boultwood, Jacqueline, Santos, Fabio P. S., Schanz, Julie, Kasahara, Senji, Ishikawa, Takayuki, Tsurumi, Hisashi, Takaori-Kondo, Akifumi, Kiguchi, Toru, Polprasert, Chantana, Bennett, John M., Klimek, Virginia M., Savona, Michael R., Belickova, Monika, Ganster, Christina, Palomo, Laura, Sanz, Guillermo, Ades, Lionel, Della Porta, Matteo Giovanni, Elias, Harold K., Smith, Alexandra G., Werner, Yesenia, Patel, Minal, Viale, Agnès, Vanness, Katelynd, Neuberg, Donna S., Stevenson, Kristen E., Menghrajani, Kamal, Bolton, Kelly L., Fenaux, Pierre, Pellagatti, Andrea, Platzbecker, Uwe, Heuser, Michael, Valent, Peter, Chiba, Shigeru, Miyazaki, Yasushi, Finelli, Carlo, Voso, Maria Teresa, Shih, Lee-Yung, Fontenay, Michaela, Jansen, Joop H., Cervera, José, Atsuta, Yoshiko, Gattermann, Norbert, Ebert, Benjamin L., Bejar, Rafael, Greenberg, Peter L., Cazzola, Mario, Hellström-Lindberg, Eva, Ogawa, Seishi, and Papaemmanuil, Elli

Published
2021
Full Text
View/download PDF

34. An Agenda to Advance Research in Myelodysplastic Syndromes: A TOP 10 Priority List From the First International Workshop in MDS

Author

Stahl, Maximilian, Abdel-Wahab, Omar, Wei, Andrew H., Savona, Michael R., Xu, Mina L., Xie, Zhuoer, Taylor, Justin, Starczynowski, Daniel, Sanz, Guillermo F., Sallman, David A., Santini, Valeria, Roboz, Gail J., Patnaik, Mrinal M., Padron, Eric, Odenike, Olatoyosi, Nazha, Aziz, Nimer, Stephen D., Majeti, Ravindra, Little, Richard F., Gore, Steven, List, Alan F., Kutchroo, Vijay, Komrokji, Rami S., Kim, Tae Kon, Kim, Nina, Hourigan, Christopher S., Hasserjian, Robert P., Halene, Stephanie, Griffiths, Elizabeth A., Greenberg, Peter L., Figueroa, Maria, Fenaux, Pierre, Efficace, Fabio, DeZern, Amy E., Della Porta, Matteo G., Daver, Naval G., Churpek, Jane E., Carraway, Hetty E., Brunner, Andrew M., Borate, Uma, Bennett, John M., Bejar, Rafael, Boultwood, Jacqueline, Loghavi, Sanam, Bewersdorf, Jan Philipp, Platzbecker, Uwe, Steensma, David P., Sekeres, Mikkael A., Buckstein, Rena J., Zeidan, Amer M., Stahl, Maximilian, Abdel-Wahab, Omar, Wei, Andrew H., Savona, Michael R., Xu, Mina L., Xie, Zhuoer, Taylor, Justin, Starczynowski, Daniel, Sanz, Guillermo F., Sallman, David A., Santini, Valeria, Roboz, Gail J., Patnaik, Mrinal M., Padron, Eric, Odenike, Olatoyosi, Nazha, Aziz, Nimer, Stephen D., Majeti, Ravindra, Little, Richard F., Gore, Steven, List, Alan F., Kutchroo, Vijay, Komrokji, Rami S., Kim, Tae Kon, Kim, Nina, Hourigan, Christopher S., Hasserjian, Robert P., Halene, Stephanie, Griffiths, Elizabeth A., Greenberg, Peter L., Figueroa, Maria, Fenaux, Pierre, Efficace, Fabio, DeZern, Amy E., Della Porta, Matteo G., Daver, Naval G., Churpek, Jane E., Carraway, Hetty E., Brunner, Andrew M., Borate, Uma, Bennett, John M., Bejar, Rafael, Boultwood, Jacqueline, Loghavi, Sanam, Bewersdorf, Jan Philipp, Platzbecker, Uwe, Steensma, David P., Sekeres, Mikkael A., Buckstein, Rena J., and Zeidan, Amer M.

Published
2023

35. Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes

Author

Bernard, Elsa, primary, Ossa, Juan E. Arango, additional, Tuechler, Heinz, additional, Greenberg, Peter L., additional, Hasserjian, Robert P., additional, Nannya, Yasuhito, additional, Devlin, Sean M., additional, Creignou, Maria, additional, Pinel, Philippe, additional, Monier, Lily, additional, Medina-Martinez, Juan S., additional, Domenico, Dylan, additional, Jädersten, Martin, additional, Germing, Ulrich, additional, Sanz, Guillermo, additional, van de Loosdrecht, Arjan A., additional, Kosmider, Olivier, additional, Follo, Matilde Y., additional, Thol, Felicitas, additional, Zamora, Lurdes, additional, Pinheiro, Ronald F., additional, Pellagatti, Andrea, additional, Haase, Detlef, additional, Fenaux, Pierre, additional, Belickova, Monika, additional, Savona, Michael R., additional, Klimek, Virginia M., additional, Santos, Fabio P., additional, Boultwood, Jacqueline, additional, Kotsianidis, Ioannis, additional, Santini, Valeria, additional, Solé, Francesc, additional, Platzbecker, Uwe, additional, Heuser, Michael, additional, Valent, Peter, additional, Ohyashiki, Kazuma, additional, Finelli, Carlo, additional, Voso, Maria Teresa, additional, Shih, Lee-Yung, additional, Fontenay, Michaela, additional, Jansen, Joop H., additional, Cervera, José, additional, Gattermann, Norbert, additional, Ebert, Benjamin L., additional, Bejar, Rafael, additional, Malcovati, Luca, additional, Cazzola, Mario, additional, Ogawa, Seishi, additional, Hellström-Lindberg, Eva, additional, and Papaemmanuil, Elli, additional

Published
2023
Full Text
View/download PDF

36. Supplemental Figure 1 (Transformation Assays) and Supplemental Figure 2 (Colony Assays) from The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I

Author

Maxson, Julia E., primary, Luty, Samuel B., primary, MacManiman, Jason D., primary, Paik, Jason C., primary, Gotlib, Jason, primary, Greenberg, Peter, primary, Bahamadi, Swaleh, primary, Savage, Samantha L., primary, Abel, Melissa L., primary, Eide, Christopher A., primary, Loriaux, Marc M., primary, Stevens, Emily A., primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

37. Data from The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I

Author

Maxson, Julia E., primary, Luty, Samuel B., primary, MacManiman, Jason D., primary, Paik, Jason C., primary, Gotlib, Jason, primary, Greenberg, Peter, primary, Bahamadi, Swaleh, primary, Savage, Samantha L., primary, Abel, Melissa L., primary, Eide, Christopher A., primary, Loriaux, Marc M., primary, Stevens, Emily A., primary, and Tyner, Jeffrey W., primary

Published
2023
Full Text
View/download PDF

40. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

Author

Zeidan, Amer M., primary, Platzbecker, Uwe, additional, Garcia-Manero, Guillermo, additional, Sekeres, Mikkael A., additional, Fenaux, Pierre, additional, DeZern, Amy E., additional, Greenberg, Peter L., additional, Savona, Michael R., additional, Jurcic, Joseph G., additional, Verma, Amit K., additional, Mufti, Ghulam J., additional, Buckstein, Rena, additional, Santini, Valeria, additional, Shetty, Jeevan K., additional, Ito, Rodrigo, additional, Zhang, Jennie, additional, Zhang, George, additional, Ha, Xianwei, additional, Backstrom, Jay T., additional, and Komrokji, Rami S., additional

Published
2022
Full Text
View/download PDF

43. Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Author

Sirenko, Maria, primary, Bernard, Elsa, additional, Beck, David B., additional, Creignou, Maria, additional, Domenico, Dylan, additional, Farina, Andrea, additional, Arango, Juan E, additional, Kosmider, Olivier, additional, Hasserjian, Robert P., additional, Jadersten, Martin, additional, Germing, Ulrich, additional, Sanz, Guillermo, additional, van de Loosdrecht, Arjan A., additional, Follo, Matilde Y, additional, Thol, Felicitas R., additional, Zamora, Lurdes, additional, Pinheiro, Ronald Feitosa, additional, Pellagatti, Andrea, additional, Elias, Harold K., additional, Haase, Detlef, additional, Ganster, Christina, additional, Ades, Lionel, additional, Tobiasson, Magnus, additional, Palomo, Laura, additional, Della Porta, Matteo G., additional, Huberman, Kety, additional, Fenaux, Pierre, additional, Belickova, Monika, additional, Savona, Michael R., additional, Klimek, Virginia M., additional, Santos, Fabio Pires de Souza, additional, Boultwood, Jacqueline, additional, Kotsianidis, Ioannis, additional, Santini, Valeria, additional, Solé, Francesc, additional, Platzbecker, Uwe, additional, Heuser, Michael, additional, Valent, Peter, additional, Finelli, Carlo, additional, Voso, Maria Teresa, additional, Shih, Lee-Yung, additional, Ogawa, Seishi, additional, Fontenay, Michaela, additional, Jansen, Joop H., additional, Cervera, Jose, additional, Ebert, Benjamin L., additional, Bejar, Rafael, additional, Greenberg, Peter L, additional, Gattermann, Norbert, additional, Malcovati, Luca, additional, Cazzola, Mario, additional, Hellström-Lindberg, Eva, additional, and Papaemmanuil, Elli, additional

Published
2022
Full Text
View/download PDF

44. Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Author

Pfeilstocker, Michael, primary, Tuechler, Heinz, additional, Ades, Lionel, additional, Cermak, Jaroslav, additional, Chermat, Fatiha, additional, Della Porta, Matteo G., additional, Fenaux, Pierre, additional, Garcia-Manero, Guillermo, additional, Germing, Ulrich, additional, Haase, Detlef, additional, Kuendgen, Andrea, additional, Luebbert, Michael, additional, Magalhaes, Silvia Maria Meira, additional, Malcovati, Luca, additional, Miyazaki, Yasushi, additional, Sanz, Guillermo, additional, Santini, Valeria, additional, Sekeres, Mikkael A., additional, Walter, Matthew J, additional, Valent, Peter, additional, and Greenberg, Peter L, additional

Published
2022
Full Text
View/download PDF

45. An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS)

Author

Stahl, Maximilian, primary, Abdel-Wahab, Omar, additional, Wei, Andrew H., additional, Savona, Michael R, additional, Xu, Mina L, additional, Xie, Zhuoer, additional, Taylor, Justin, additional, Starczynowski, Daniel T, additional, Sanz, Guillermo F., additional, Sallman, David A., additional, Santini, Valeria, additional, Roboz, Gail J., additional, Patnaik, Mrinal M., additional, Padron, Eric, additional, Odenike, Olatoyosi, additional, Nazha, Aziz, additional, Nimer, Stephen D, additional, Majeti, Ravindra, additional, Little, Richard F, additional, Gore, Steven D, additional, List, Alan F., additional, Kuchroo, Vijay, additional, Komrokji, Rami S., additional, Kim, Tae Kon, additional, Kim, Nina, additional, Hourigan, Christopher S, additional, Hasserjian, Robert P, additional, Halene, Stephanie, additional, Griffiths, Elizabeth A, additional, Greenberg, Peter L., additional, Figueroa, Maria E., additional, Fenaux, Pierre, additional, Efficace, Fabio, additional, DeZern, Amy E., additional, Della Porta, Matteo G, additional, Daver, Naval G., additional, Churpek, Jane E., additional, Carraway, Hetty E, additional, Brunner, Andrew M., additional, Borate, Uma, additional, Bennett, John M, additional, Bejar, Rafael, additional, Boultwood, Jacqueline, additional, Loghavi, Sanam, additional, Bewersdorf, Jan Philipp, additional, Platzbecker, Uwe, additional, Steensma, David P., additional, Sekeres, Mikkael A., additional, Buckstein, Rena J., additional, and Zeidan, Amer M., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results